What is the ticker symbol for Insight Molecular Diagnostics?

Insight Molecular Diagnostics trades under the ticker IMDX on NASDAQ.

What sector does Insight Molecular Diagnostics operate in?

Insight Molecular Diagnostics is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze IMDX in a portfolio?

PortView shows IMDX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Insight Molecular Diagnostics (IMDX) Stock Analysis

NASDAQHealthcareMedical - Diagnostics & Research

$3.89+1.30%

1-year price historyRange $2.47 – $8.48

52-week range$3.89

$2.40$8.51

What Insight Molecular Diagnostics does

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

Key metrics

Market cap

$125.61M

P/E (TTM)

-2.61

EPS (TTM)

$-1.49

Beta

1.82

Dividend yield

0.00%

Revenue / share

$0.05

50-day avg

$4.76

200-day avg

$5.29

52-week high

$8.51

52-week low

$2.40

CEO

Joshua Riggs

ETFs linked to IMDX

Broad-market and Healthcare sector ETFs an investor holding Insight Molecular Diagnostics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how IMDX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze IMDX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Insight Molecular Diagnostics?: Insight Molecular Diagnostics trades under the ticker IMDX on NASDAQ.
Which exchange is IMDX listed on?: IMDX is listed on NASDAQ.
What sector does Insight Molecular Diagnostics operate in?: Insight Molecular Diagnostics is classified in the Healthcare sector (Medical - Diagnostics & Research industry).
How can PortView help analyze IMDX in a portfolio?: PortView shows IMDX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.